Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.

Matthew Krebs, Amy Branson, Shaun Barber, Charlotte Poile, Amy King, Alastair Greystoke, Sam Moody, Luke Nolan, Molly Scotland, Liz Darlison, Amrita Bajaj, Bruno Morgan, Cassandra Brookes, Peter Wells-Jordan, Catherine Richards, Anne Thomas, Dean Fennell

Research output: Contribution to journal › Meeting Abstract

Fingerprint

Dive into the research topics of 'Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science